PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

2018 SABCS FLEX Trials in Progress Poster

AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Lomis, Pat Whitworth, Esther Rehmus, Gordon Srkalovic, Laura Lee, Peter Blumencranz, Paul Baron, Blanche Mavromatis, Sarah Untch, Lisa Blumencranz, Tina Treece, Erin Yoder, William Audeh. DESCRIPTION: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Read More

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, ISPY2 TRIAL Investigators, Laura Esserman and Laura van ‘t Veer DESCRIPTION: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY2 breast cancer patients BluePrint® Read More

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Shelly Lo, MD; William Audeh, MD; Rubina Qamar, MD; Raye Budway, MD; Ellis Levine, MD; Pat Whitworth, MD; Blanche Mavromatis, MD; Robin Zon, MD; Dwight Oldham, MD; Sarah Untch, MS; Tina Treece, PhD; Lisa Blumencranz, PhD; Hatem Soliman, MD ABSTRACT: Read More

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS:  Laura J. Esserman, MD, MBA; Christina Yau, PhD; Carlie K. Thompson, MD; Laura J. van 't Veer, PhD; Alexander D. Borowsky, MD; Katherine A. Hoadley, PhD; Nicholas P. Tobin, PhD; Bo Nordenskjöld, MD, PhD; Tommy Fornander, MD, PhD; Olle Stål, PhD; Christopher C. Benz, Read More

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Laura J. van ‘t Veer, Christina Yau, Nancy Y. Yu, Christopher C. Benz, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Laura J. Esserman, Linda Sofie Lindström SUMMARY: 20yr BCSS and 10yr DMFS analysis of MammaPrint High Risk vs Low Risk patients Read More

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep 22, 2017. https://doi.org/10.4048/jbc.2017.20.3.246 AUTHORS:  Areej Fatima, Fomaz Tariq, Muhammad Faraz Arshad Malik, Muhammad Qasim, and Farhan Haq SUMMARY:  DNA copy number variations (CNVs) in realtion to MammaPrint 70-genes (cell line and TCGA data). Read more: Copy Number Profiling of MammaPrint..._Fatima Read More

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study

PUBLICATION: Journal of Clinical Oncology 35, no. 24 (August 20, 2017) 2814-2819. DOI: 10.1200/JCO.2016.70.3959. AUTHORS: Anne Kuijer, Marieke Straver, Bianca den Dekker, Annelotte C.M. van Bommel, Sjoerd G. Elias, Carolien H. Smorenburg, Jelle Wesseling, Sabine C. Linn, Emiel J.Th. Rutgers, Sabine Siesling, and Thijs van Dalen SUMMARY: Prospective, observational Dutch Read More